Client issue
A leading pharmaceutical company sought support from CRA’s Life Sciences experts in understanding payer and hospital access decision maker (HADM) perspectives for a unique product to treat acute ischemic stroke (AIS) in both the inpatient and outpatient care settings. The client was particularly interested in understanding which stakeholders would be most significant in determining the potential for patient treatment, how the product would be funded given the care setting dynamic, and pricing/access potential.
CRA approach
We developed a detailed landscape assessment to align understanding of the disease, the current treatment paradigm, future expected competitive landscape, and the pricing and access environment. We also developed a “financial flow” detailing how a treatment for AIS would be funded in each care setting (i.e., inpatient and outpatient). We conducted primary market research with payers and HADMs to understand perspectives on the evolving landscape, value drivers for AIS assets (including specific clinical trial design elements), pricing and market access potential, and to refine our financial flow. The project culminated in the development of recommendations on the price/access opportunity and what endpoints the clinical trial program should include to support/enhance the opportunity.
Client impact
The outputs of this project helped our client understand the most important product, clinical trial design elements, and funding dynamics expected to impact HADM and payer coverage for a unique AIS treatment, and to inform decisions around the Phase 3 clinical trial program.
